Intuitive Surgical, Inc.
DELTAX CAPITAL | PUBLIC COMPANY RESEARCH
JULY 22 2026
Intuitive Surgical, Inc. (NASDAQ: ISRG) develops the da Vinci surgical systems and Ion robotic lung biopsy platform. This report examines whether its leadership in robotic-assisted surgery can endure growing competition, and what that durability justified after a steep decline in its share price.
WHAT WE FOUND.
The installed base supports recurring revenue. Surgeon training and hospital workflows reinforce the da Vinci platform. Instruments, accessories, service, and operating leases accounted for roughly 85% of second-quarter 2026 revenue by the report’s calculation.
Competition starts with new adoption. Medtronic’s Hugo, CMR’s Versius Plus, and Johnson & Johnson’s Ottava introduce credible challengers. Winning hospitals adopting robotics for the first time and pressuring instrument prices could weaken Intuitive before its existing installed base visibly erodes.
Demand pressure is real; duration is unresolved. Second-quarter revenue grew 19%, while U.S. elective procedure growth moderated amid insurance-coverage pressure. The report treats the persistence of that pressure as an open question.
The base discounted cash flow estimate was $324.95 per share, below the $350.06 closing price on July 21, 2026. Despite the roughly 42% decline from the January high, the report finds an exceptional business at a demanding price. The valuation depends on sustained growth and higher operating margins, and remains sensitive to the assumed required return.
Read the full Intuitive Surgical research report (PDF)
Prepared by Matthew Schaller, Founder and Chief Investment Officer, DeltaX Capital LLC, a South Carolina-registered investment adviser serving the Charleston area.
General, impersonal research; not individualized investment advice or a recommendation to buy, sell, or hold. Valuation estimates are not price targets or predictions.